Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transmembrane p24 trafficking protein 3(
TMED3
) is a metastatic suppressor in colon cancer, but its function in the progression of
hepatocellular carcinoma
(
HCC
) is unknown. Here, we report that
TMED3
was up-regulated in
HCC
and portal vein tumor thrombus.
TMED3
up-regulation in
HCC
was significantly correlated with aggressive characteristics and predicted poor prognosis in
HCC
patients.
TMED3
overexpression in
HCC
cell lines promoted cell migration and invasion. In contrast,
TMED3
knockdown suppressed
HCC
metastasis both in vitro and in vivo. Gene microarray analysis revealed decreased IL-11 expression in
TMED3
-knockdown cells. We propose that
TMED3
promotes
HCC
metastasis through IL-11/STAT3 signaling. Taken together, these findings demonstrate that
TMED3
promotes
HCC
metastasis and is a potential prognostic biomarker in
HCC
.
...
PMID:TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. 2790 Oct 21
Transmembrane p24 trafficking protein 3 (
TMED3
) is a metastatic suppressor in colon cancer and
hepatocellular carcinoma
. However, its function in the progression of clear cell renal cell carcinoma (ccRCC) is unknown. Here, we report that
TMED3
could be a new prognostic marker for ccRCC. Patient data were extracted from cohorts in the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Differential expression of
TMED3
was observed between the low stage (Stage I and II) and high stage (Stage III and IV) patients in the TCGA and ICGC cohorts and between the low grade (Grade I and II) and high grade (Grade III and IV) patients in the TCGA cohort. Further, we evaluated
TMED3
expression as a prognostic gene using Kaplan-Meier survival analysis, multivariate analysis, the time-dependent area under the curve (AUC) of Uno's C-index, and the AUC of the receiver operating characteristics at 5 years. The Kaplan-Meier analysis revealed that
TMED3
overexpression was associated with poor prognosis for ccRCC patients. Analysis of the C-indices and area under the receiver operating characteristic curve further supported this. Multivariate analysis confirmed the prognostic significance of
TMED3
expression levels (
P
= 0.005 and 0.006 for TCGA and ICGC, respectively). Taken together, these findings demonstrate that
TMED3
is a potential prognostic factor for ccRCC.
...
PMID:Prognostic Role of
TMED3
in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis. 3105 5